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Background: Cardiac surgery-associated acute kidney injury (CSA-AKI) is a common complication following
coronary bypass graft (CABG) surgery. Multi-factorial causes of CSA-AKI involve oxidative stress and inflammation.
Erythropoietin (EPO) has been shown from many studies to have a reno-protective effect. The present study was
conducted to examine the role of EPO in preventing CSA-AKI.
Methods: This prospective, randomized, double-blind, placebo-controlled trial was conducted in the Cardiovascular
and Thoracic Unit. One hundred patients randomly received either 200 U/kg of rHuEPO (n = 50) or saline (n = 50)
intravenously three days before operation, and rHuEPO 100 U/kg or saline at operation time. The serum creatinine
(SCr), estimated glomerular filtration rate (eGFR) and urine neutrophil gelatinase-associated lipocaline (NGAL) were
measured in order to evaluate renal injury following CABG.
Results: The incidence of CSA-AKI was significantly lower in rHuEPO group (14%) when compared with the
placebo group (38%; p < 0.01). The mean intensive care unit (ICU) and hospital stays of the rHuEPO group were
significantly shorter than the placebo group (p < 0.01). Postoperative increases in SCr and decreases in eGFR were
significantly lower in the rHuEPO group than the placebo group (p < 0.05). The mean urine NGAL in rHuEPO group
was significantly lower than the placebo group at 3 hr, 6 hr, 12 hr and 18 hr after CABG (p < 0.05), respectively.
Conclusions: Prophylaxis administration with intravenous rHuEPO before cardiac surgery decreased the incidence
of CSA-AKI and urine NGAL with reduced days in ICU and hospital in elective CABG patients.
Trial registration: ClinicalTrials.gov: NCT01066351
Keywords: Erythropoietin, Acute kidney injury, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Cardiac surgery* Correspondence: adis_tasanarong@hotmail.com
1Nephrology Unit, Department of Medicine, Faculty of Medicine, Thammasat
University (Rangsit Campus), Khlong Nung, Khlong Luang, Pathumthani
12121, Thailand
Full list of author information is available at the end of the article
© 2013 Tasanarong et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Tasanarong et al. BMC Nephrology 2013, 14:136 Page 2 of 10
http://www.biomedcentral.com/1471-2369/14/136Background
Acute kidney injury (AKI) following cardiac surgery is
the second most common cause of AKI in critically ill
patients [1]. The incidence of cardiac surgery-associated
acute kidney injury (CSA-AKI) varies between 7.7 to
42% and is associated with prolonged admission in the
intensive care unit (ICU) and longer hospital stay [2,3].
CSA-AKI requiring renal replacement therapy (RRT)
following coronary artery bypass grafting (CABG) sur-
gery occurs in approximately 0.7 to 3.5% and is associ-
ated with an increase in mortality rate [4,5]. Minimal
increase of serum creatinine (SCr) correlated with in-
crease mortality and affected long-term survival after
cardiac surgery [6,7]. Multiple causes of CSA-AKI have
been proposed, including cardiovascular compromise,
prolonged cardiopulmonary bypass (CPB) exposure,
hemolysis, hypothermia, decline of renal perfusion, and
reperfusion after operation [8]. These causes could in-
duce ischemic reperfusion injury, generate reactive oxy-
gen species and activate inflammatory pathways [9].
Many studies have tried to demonstrate the advantage of
various pharmacologic interventions to prevent CSA-
AKI such as dopamine, N-acetylcysteine, statin, and
fenoldopam but the results have been conflicting [10,11].
Erythropoietin (EPO) is a 30 kDa glycoprotein pro-
duced by kidney that regulates red blood cell production
in the bone marrow [12]. Recombinant human erythro-
poietin (rHuEPO) has been considered as a novel
reno-protective therapy beyond the hematopoietic effect
in AKI and chronic kidney disease (CKD) [13,14].
rHuEPO plays an important role as an anti-apoptotic,
anti-inflammation and anti-oxidant properties in many
models of kidney disease [15-17]. In experimental
models of AKI, rHuEPO administration before, during
or even after injury has attenuated kidney damage in
AKI [12,18] and has slowed the progression during
chronic kidney injury [18]. However, the few clinical tri-
als in humans have produced the conflicting results re-
garding to the reno-protective effect of rHuEPO in AKI.
Similarly, previous clinical trials demonstrated that the
early anemia treatment in CKD patients with rHuEPO
did not produce a consistent effect on slowing the pro-
gression of CKD [19-22].
Because of the different diagnostic criteria of CSA-AKI
that was based on SCr and/or urine output [23,24], the
use of these criteria still have many limitations, espe-
cially in the reliability of SCr in AKI patients and lack of
real-time estimation of glomerular filtration rate (eGFR).
Furthermore, SCr is an unreliable biomarker during AKI
in kidney function because many factors can affect SCr
level including creatinine generation by muscle catabol-
ism and diet, age, hydration status and renal tubular se-
cretion [25]. Changes in SCr are delayed in time after
kidney injury [26]. Thus, the development of novel AKIrelated biomarkers could help the physicians in the early
detection of CSA-AKI [26,27].
In the last decade, many publications have evaluated the
accuracy and reliability of novel urinary and serum bio-
markers like neutrophil gelatinase-associated lipocalin
(NGAL) for the early detection and/or predict the progno-
sis of AKI [28]. However, there remains the space between
the damage in biological processes and the clinical presen-
tation during AKI, so such markers have not yet found a
place in routine clinical practice [29,30]. Although, none
novel biomarkers has the consensus to approach in clinical
decision making in diagnosis patients with AKI, but NGAL
detected patients with subclinical AKI in spite of un-
changed SCr [31]. In addition, delayed diagnosis of AKI
based on SCr changing could explain some negative results
of the interventions in many clinical trials [32]. NGAL is a
25 kDa protein covalently bound to gelatinase in neutro-
phils and is usually expresses at very low levels in several
human tissues, including kidney, lung, stomach, and colon
[33,34]. During AKI, NGAL expression is markedly in-
creased in the injured distal nephron epithelia, and is not
reabsorbed by the damaged proximal tubules resulting in
an elevation of urinary NGAL [35]. NGAL protein was eas-
ily detected in the blood and urine soon after AKI in animal
and human diseases [36,37] and used in the detection of
CSA-AKI in patients undergoing cardiac surgery [38,39].
Given the uncertainty of the use of rHuEPO for renal
protection and the promising use of NGAL for detecting
AKI, we conducted a prospective, randomized, double-
blind, placebo-controlled trial to evaluate the reno-
protective effect of rHuEPO when started three days
prior to the onset of cardiac surgery and at the operation
time. This early start is intended as a means of
preventing AKI in elective CABG patients. The advan-
tage of rHuEPO was evaluated on the incidence of CSA-
AKI, clinical outcomes and changing of urine NGAL.
Methods
Patient population
Study patients were aged at least 18 years who were
scheduled for elective CABG using the CPB technique at
Thammasat Chalerm Prakiat Hospital during the period
from January 2010 to March 2011 were included in
the study. The protocol was approved by the Ethics
Committee of the Faculty of Medicine at Thammasat
University. All patients provided written, informed con-
sent to participate in the study. Patients with AKI before
randomization, CKD stage 5 or unstable renal function
(as evidenced by a change in SCr of ≥ 0.3 mg/dL, or ≥
50%, within 14 days prior to the study), using the
nephrotoxic drugs and/or contrast media administration
within two weeks before operation and using rHuEPO
prior to CABG were excluded. Subjects were also ex-
cluded if they had a known allergy to any of the
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genic shock or emergent CABG. The study was done in
full compliance with the Declaration of Helsinki. This
trial was registered in the Protocol Registration System
(ClinicalTrials.gov Identifier: NCT01066351).
Study protocol
This was a single center with balanced randomization
1:1 ratios, double-blind, placebo controlled trial. Treat-
ment assignment among the two groups was determined
by blocked randomization. After recruitment, three days
before the operation, sealed envelopes containing the al-
location group were opened by nurses who did not par-
ticipate in the study. All patients were enrolled into this
study were randomized into two groups: the patients
who received rHuEPO (rHuEPO group) and 0.9% saline
(placebo group). The same nurse and perfusionist pre-
pared the treatments that were blindly given to the re-
search coordinator. Patients and investigators were also
blinded to group assignment. Pairs of identical 0.3 ml sy-
ringes containing either rHuEPO (5,000 U, Recormon,
Roche) or saline were prepared and stored. Patients re-
ceived an intravenous dose of 200 U/kg or saline three
days before operation and either 100 U/kg of rHuEPO
or saline intravenously at the operation time.
Demographic and baseline characteristics including
patient age, sex, blood pressure, and co-morbidities were
collected at time of group assignment. In addition, intra-
operative data, operation time, arterial clamp time, the
amount of fluid or blood infused and the urine output
were collected.
Urine and serum sample collections and storage
Blood samples were obtained for the measurement of
complete blood count (CBC) and percent of reticulocyte
count three days before the operation (baseline), 3 to
6 hr before the operation, and daily CBC for five days
post-operation. Baseline SCr was measured at 6 to 12 hr
prior to operation and post-operative daily at least for
five days in all patients. eGFR was calculated using the
Cockroft-Gault equation. All laboratory parameters were
performed in a single, hospital-based laboratory using
standard methods. Serial urine samples were collected at
baseline and 3, 6, 12, 18 and 24 h after operation.
Samples were centrifuged at 2,000 g for 5 min and the
supernatants stored at −70°C until assayed.
Urinary NGAL concentration was measured using
a commercial ELISA kit (Antibody Shop, Gentofte,
Denmark), following the manufacturer’s instructions. All
urine specimens were diluted to achieve concentration
for optimal density before performing the ELISA assay
to fit the concentrations of respective NGAL protein in
the linear range of the standard curve. The inter-assay
and intra-assay coefficients of variation for NGAL were< 5%. The measurements were made in duplicate and in
a blinded fashion.
Study end points
The primary endpoint of this study was the incidence of
CSA-AKI in rHuEPO compared with placebo group.
The definition of CSA-AKI is defined as a ≥ 0.3 mg/dl
or ≥ 50% increase in SCr levels from baseline within the
first 48 hr post-operation according to the newer criteria
of AKI from KDIGO guideline 2012. Secondary end-
points consisted of comparative changes in SCr, eGFR
and urine NGAL during the first three postoperative
days, postoperative complications, length of stay in the
intensive care unit (ICU) and hospital, a requirement for
renal replacement therapy (RRT) and all causes hospital
mortality between rHuEPO and placebo groups.
Sample size
The sample size was calculated to demonstrate a reduc-
tion in the incidence of CSA-AKI from 40% in the pla-
cebo group to 15% in the rHuEPO group. With the use
of a two-sided X2 test with a significance level of 0.05
and a power of 90%, the sample size in each group was
65 patients. However, the statistic significant between
both groups become since the population size in each
group was 50 patients. Therefore, a total of 100 patients
were randomized in the present study.
Statistical analysis
Data were expressed as a mean ± SD for continuous vari-
ables and as percentages for discrete variables. Continu-
ous data were analyzed by the Student’s t test for equal
variance or Mann–Whitney test for unequal variance,
and categorical valuables were investigated by the Pear-
son χ2 or Fisher’s exact test. A two-sided p value < 0.05
was considered significant. Two-way analysis of variance
was utilized to compare continuous variables over time
between the two groups with Bonferroni post-hoc test
for each time point. Statistical analyses were performed
using SPSS (Version 15.0. for Windows; SPSS, Inc.) and
significance was assigned when p values < 0.05.
Results
A total of 185 patients referred for cardiac surgery were
screened between January 2010 and March 2011
(Figure 1). Of these patients, 116 patients met the inclu-
sion criteria and were enrolled in the study. Fourteen pa-
tients were excluded from the study because nine
patients refused to participate, two patients suffered
from congestive heart failure, and three patients devel-
oped AKI. Finally, 102 patients were randomized and al-
located to one of the two treatment arms between the
placebo and rHuEPO group. One patient in the rHuEPO
and one from the placebo group were excluded because
Figure 1 Flow diagram on enrollment of patients into the study.
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ation. Consequently, 100 patients received their assigned
treatments to the placebo (n = 50) or rHuEPO (n = 50)
group. The baseline characteristics and intra-operative
information for these study participants are shown in
Table 1. There were no statistically significant differences
between the two groups regarding clinical characteris-
tics, especially existing co-morbidities and preoperative
medications. In addition, preoperative hemoglobin,
hematocrit, reticulocyte count, SCr and eGFR were com-
parable between the two groups. The operation time, ar-
terial clamp time, central venous pressure, fluid intake
and urine output during operation were equivalent be-
tween both groups.
The change in reticulocyte count, hematocrit, SCr and
eGFR are shown in Table 2. Baseline reticulocyte count
was similar between the two groups. There was a signifi-
cant increase in the percent reticulocyte count following
administration of the first dose of rHuEPO in rHuEPO
group (1.11 ± 0.63 to 1.6 ± 0.82; p < 0.01) while no sig-
nificant change occurred in the placebo group (1.19 ±
0.66 to 1.12 ± 0.56) at operative day. There was nosignificant difference between the two groups in baseline
and postoperative hematocrit. A comparison of the two
groups, baseline SCr and eGFR showed no significant
differences. In the placebo group, SCr was higher than
the baseline at 24, 48 and 72 hr after operation. In con-
trast, SCr in the rHuEPO group was higher than the
baseline at 24 hr but turned down like the baseline at
48 hr and was lower than the baseline at 72 hr after op-
eration (Figure 2A). Moreover, SCr at 48 hr post-
operation in the placebo group was significantly higher
than the rHuEPO group (p < 0.05), (Table 2). In the pla-
cebo group, eGFR was lower than the baseline at 24, 48
and 72 hr after operation (p < 0.05) but eGFR in
rHuEPO group was no significant change from the base-
line at 24, 48, and 72 hr after operation (Figure 2B). In
addition, eGFR was significantly lower in the placebo
than the rHuEPO group at 24, 48 and 72 hr after oper-
ation (p < 0.05), respectively (Table 2).
Primary and secondary endpoints are shown in Table 3.
CSA-AKI occurred in 26% in the present study. CSA-
AKI developed 38% in the placebo group compared with
14% in the rHuEPO group (p < 0.01). Postoperative
Table 1 Baseline characteristics and intra-operative data of enrolled patients randomized to placebo or rHuEPO group
Placebo group (n = 50) rHuEPO group (n = 50) p value
Age (years) 60 ± 16 63 ± 16 0.39
Sex: Male (%) 52 62 0.31
Underlining Disease:
Diabetes mellitus (%) 34 27 0.54
Hypertension (%) 63 79 0.15
Dyslipidemia (%) 38 36 0.92
Preoperative medication:
ACE inhibitor (%) 44 46 0.72
Angiotensin II recertor blocker (%) 22 24 0.86
Beta blocker (%) 46 50 0.62
Calcium channel blocker (%) 34 36 0.68
Diuretic (%) 26 30 0.24
Platelet inhibitor (%) 74 82 0.16
Statin (%) 62 60 0.84
Serum creatinine (SCr), mg/dL 1.05 ± 0.45 1.05 ± 0.27 0.94
eGFR (mL/min/1.73 m2) 67 ± 33 64 ± 29 0.44
eGFR > 60 (%) 48 38 0.48
eGFR < 60 (%) 52 62 0.32
Hemoglobin (g/dL) 12.2 ± 1.9 12.3 ± 1.7 0.72
Hematocrit (%) 36.2 ± 6.6 37.1 ± 5.2 0.45
Reticulocyte count (%) 1.19 ± 0.66 1.11 ± 0.63 0.53
Intra-operative data:
Operation time (minutes) 353 ± 76 341 ± 88 0.44
Arterial clamp time (minutes) 87 ± 31 82 ± 38 0.52
Central venous pressure (cm H2O) 4.81 ± 4.07 4.52 ± 3.93 0.72
Intraoperative intake (mL) 1,628 ± 660 1,530 ± 477 0.55
Intraoperative output (mL) 958 ± 673 1172 ± 973 0.34
Intraoperative urine output (mL/kg/hour) 2.89 ± 1.73 2.96 ± 2.46 0.89
eGFR indicates estimated glomerular filtration rate.
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mean ICU and hospital stay of the rHuEPO group were
4 ± 1 and 11 ± 2 days, which were significantly shorter
than the placebo group 7 ± 4 and 17 ± 9 days (p < 0.01),
respectively. Two patients in the placebo group required
RRT but none in the rHuEPO group during hospital
stay. Two patients in the placebo group died in the hos-
pital from sepsis, but no deaths occurred in the rHuEPO
group. There was no hypertension, symptomatic throm-
bosis, myocardial infarction, stroke, seizures or other
serious adverse events in the patients who received the
rHuEPO. While, there were no significant differences
between the rHuEPO and placebo groups regarding inci-
dence of adverse events.
Baseline and post-operative urine NGAL levels were
shown in Table 4. Baseline urine NGAL concentrations
were similar in patients between both groups butbecame higher than baseline at all time points within
the first 24 hours in both groups. The mean urine
NGAL concentrations in the rHuEPO group were sig-
nificantly lower than the placebo group at 3 hr (p <
0.05), 6 hr (p < 0.01), 12 hr (p < 0.01) and 18 hr (p < 0.05)
after operation. In patients who develop CSA-AKI, the
urine NGAL in rHuEPO group were also significantly
lower than the placebo group at all postoperative time
points (p < 0.05). While, there was no difference in urine
NGAL in patients who did not develop CSA-AKI be-
tween both groups.
Discussion
The present study is the first clinical trial that has
assessed the prophylactic regimen of intravenous
administration of rHuEPO compared with placebo at
three days before and immediate operation time in the
Table 2 Baseline reticulocyte count, hematocrit, serum creatinine and eGFR with changes after cardiac surgery in
patients randomized to placebo or rHuEPO group
Placebo group (n = 50) rHuEPO group (n = 50) p value
Reticulocyte count, %
Baseline 1.19 ± 0.66 1.11 ± 0.63 0.53
Operative day (3 days after first dose) 1.12 ± 0.56 1.60 ± 0.82 <0.01
Hematocrit (%)
Baseline 36.7 ± 5.4 37.1 ± 5.2 0.72
Day 0 Pre-operation 36.8 ± 5.8 38.0 ± 5.2 0.31
Day 0 Post-operation 27.8 ± 4.0 29.4 ± 4.9 0.08
Day 1 32.3 ± 3.1 32.7 ± 3.1 0.45
Day 2 32.3 ± 3.4 32.9 ± 3.5 0.4
Day 3 32.3 ± 3.6 33.5 ± 3.9 0.17
Serum creatinine (SCr), mg/dL 1.05 ± 0.45 1.06 ± 0.25 0.83
Baseline
Day 1 after CABG 1.42 ± 0.53 1.28 ± 0.46 0.25
Day 2 after CABG 1.35 ± 0.44 1.06 ± 0.42 <0.05
Day 3 after CABG 1.18 ± 0.62 0.96 ± 0.38 0.15
eGFR, mL/min/1.73 m2
Baseline 67 ± 33 64 ± 29 0.44
Day 1 after CABG 56 ± 25 65 ± 27 <0.05
Day 2 after CABG 51 ± 28 62 ± 25 <0.05
Day 3 after CABG 58 ± 24 68 ± 26 <0.05
eGFR indicates estimated glomerular filtration rate.
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randomized, and placebo-controlled trial has shown that
prophylaxis with rHuEPO reduced the incidence of CSA-
AKI, decreased the length of ICU and hospital stays and at-
tenuated renal injury as assessed by the sensitive biomarker
urine NGAL. Moreover, the increase in SCr and the decline
in eGFR post-operation were less in the patients with
rHuEPO prophylaxis.
Although, many therapeutic prevention strategies
have been investigated in clinical trial [10,11], but none
protocol has been proven the effective to preventing
CSA-AKI. Beyond the anti-anemic effect, the benefit of
EPO in protecting the kidneys was demonstrated to be
anti-apoptosis, anti-inflammation and anti-oxidant
[15-17]. EPO treatment has reno-protective properties
in the experimental model of renal ischemic reperfu-
sion injury when given before, during or even after the
injury [40]. In the present study, the advantage of
rHuEPO prophylaxis was demonstrated by improve the
clinical outcomes and diminish urine NGAL within the
first three hours following operation, especially in pa-
tients who developed CSA-AKI. Patients with rHuEPO
prophylaxis experienced fewer post-operative compli-
cations, no needed RRT and no deaths, although num-
bers were too small to show statistically significant
differences with the placebo group. A larger clinicaltrial is needed to assess if rHuEPO confers a survival
advantage.
Our outcomes are in agreement with the recent study
by Song et al. [41] who shown that the incidence of
CSA-AKI in patients treated with high dose of rHuEPO
at the time of anesthetic induction was significantly
lower when compared with the saline infusion in the
patients undergoing elective CABG. However, adminis-
tration with rHuEPO in the Korean study did not de-
creased the duration of ICU and hospital stays, and
there were no differences in rates of RRT and death
post-cardiac surgery. A part of protocol that similar
between the present and the Korean study was time to
inject rHuEPO immediately following induction of
anesthesia before cardiac surgery. A recent study dem-
onstrated that acute systemic and local inflammatory
response after cardiac surgery is associated with
periopertive AKI [42]. The anti-inflammatory effects of
rHuEPO explain its reno-protective effect and preopera-
tive rHuEPO has also been shown to attenuate myocar-
dial ischemic reperfusion injury by inhibiting the
systemic inflammatory response [43]. Therefore, this
might be the time to get ready for the anti-inflammatory
effect of rHuEPO before ischemic reperfusion injury
during operation that induces local and systemic inflam-
matory response. The main difference between our study
Figure 2 Mean changes of SCr (2A) and eGFR (2B) at day 1
(D1), day 2 (D2), and day 3 (D3) after operation compared with
baseline in patients randomized to placebo (black line) or
rHuEPO (gray line). *p < 0.05 compared between the placebo and
rHuEPO group.
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rHuEPO three days before cardiac surgery which may ex-
plain the excellent results in term of prevent CSA-AKI and
clinical outcomes. One could hypothesize that improve
anti-oxidant property by rHuEPO administration since
three days before ischemic reperfusion injury. The anti-
oxidant effect of EPO has been proposed in many mecha-
nisms [17]. The important mechanism is EPO increases the
number of circulating young red blood cells (RBC), which
raise the level of erythrocyte anti-oxidative enzymes [44].
The increase in circulating young RBC was demonstratedby the improvement of the reticulocyte count which peaks
three to four days after rHuEPO injection [45]. Thus,
rHuEPO administration three to four days prior to cardiac
surgery may be the optimal time to start rHuEPO and a
further dose at operation will provide continued anti-
inflammatory effect for three to four postoperative days.
Our results contrast with those of two previous studies.
Early treatment with high dose rHuEPO compared with
placebo following a rise in urine gamma glutamyl
transpeptidase and alkaline phosphatase after cardiac sur-
gery by Endre et al. [46] demonstrated no differences in
changes in SCr from the baseline at 7 days, the incidence of
CSA-AKI, duration of ICU and hospital stays, and rates of
RRT and death. Similarly, study by de Seigneux et al. [47]
demonstrated that rHuEPO administration shortly after
cardiac surgery was inefficient in preventing CSA-AKI and
could not reduce the duration of ICU and hospital stays
and death. The disadvantage of rHuEPO infusion in cardiac
surgery patients may explain from many reasons. First,
treatment with rHuEPO after subclinical renal damage or
injury could not be the appropriate time to reverse the in-
flammatory response from surgery. Second, the dose of
rHuEPO may be sub therapeutic to recover the kidney
function from AKI process. This would limit the applicabil-
ity of rHuEPO treatment post-intervention to prevent AKI
and support the use of prophylactic preoperative rHuEPO
regimen.
Studies in cardiac surgery patients reveal that minimal
change in SCr or smallest change in SCr that classified by
RIFLE criteria had the correlation with increase length of
stay in ICU, mortality and postoperative costs [6,7,48,49].
Thus, many studies have assessed novel biomarkers for the
early diagnosis AKI before rises in SCr [28,38,39]. However,
conflicting results between the changes in these biological
damage detectors and clinical AKI have limited their appli-
cation in clinical practices [29,30]. Recent study demon-
strated that subclinical AKI patients detected by a rise in
NGAL without a concomitant rise in SCr increased need of
RRT, ICU & hospital stay and hospital mortality [31]. Simi-
larly, increase urine NGAL with changes of microscopic
examination on the first day in AKI patients improved clin-
ical assessment for predicting the outcome [50]. These re-
ports could point us to confirm the advantage of NGAL to
early detection and predict the outcomes in AKI patients.
Because of urine NGAL in the present study was signifi-
cantly lower in the rHuEPO than placebo group at all time
points within first 24 hr after operation. Thus, prophylaxis
with rHuEPO could reduce the incidence of CSA-AKI by
using clinical criteria and novel biomarker assessment.
Lower urine NGAL in patients who received rHuEPO pro-
vided the evidence of reno-protective effect and correlated
with better clinical outcomes.
The present clinical trial has some limitations. First, this
study has only been conducted within a single center.
Table 3 The study outcomes in patients randomized to placebo or rHuEPO group
Placebo group (n = 50) rHuEPO group (n = 50) p value
Incidence of AKI n (%) 19 (38) 7 (14) <0.01
eGFR > 60 mL/min/1.73 m2 6/24 (25) 1/19 (5.26) 0.11
eGFR < 60 mL/min/1.73 m2 13/26 (50) 6/31 (19.35) <0.05
Postoperative complication:
Bleeding n (%) 2 (4) 1 (2) 0.56
Infection n (%) 4 (8) 2 (4) 0.41
Stroke n (%) 1 (2) 0 (0) 0.32
Cardiac arrhythmia n (%) 7 (14) 6 (12) 0.77
Myocardial infarction n (%) 1 (2) 0 (0) 0.32
Hemodialysis n (%) 2 (4) 0 (0) 0.16
Hospital stay and mortality
ICU stay (days) 7 ± 4 4 ± 1 <0.01
Hospital stay (days) 17 ± 9 11 ± 2 <0.01
Hospital deaths n (%) 2 (4) 0 (0) 0.16
eGFR indicates estimated glomerular filtration rate.
ICU indicates intensive care unit.
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resentative of incidences of CSA-AKI in patients with
normal renal function and require more sample sizes
for an adequate scope of study. Thirdly, the author
mention to anti-oxidant effect of rHuEPO prophylaxis
that indicates an increase of circulating young RBC.
So, next study needs to measure the oxidant and
anti-oxidant status in these patients. Fourthly, there is
a possibility that a multi-dose of rHuEPO before car-
diac surgery may be more effective than a single dose
in the prevention of CSI-AKI. However, this situation
needs more clinical trial to establish.Table 4 Mean urine NGAL concentrations before surgery (bas
for all patients and stratified by the presence of acute kidney
Urine NGAL (ng/ml) Baseline 3 hr
All patients
Placebo group (n = 50) 61 ± 42 164 ± 144
rHuEPO group (n = 50) 55 ± 51 105 ± 76*
Patients with acute kidney injury
Placebo group (n = 19) 65 ± 23 281 ± 151
rHuEPO group (n = 7) 62 ± 28 176 ± 41*
Patients without acute kidney injury
Placebo group (n = 31) 58 ± 50 99 ± 89
rHuEPO group (n = 43) 54 ± 54 93 ± 75
Data are expressed as mean ± S.D.
Significant differences by Bonferroni post-hoc test of ANOVA.
*p < 0.05, #p < 0.01 compared between placebo and rHuEPO group.Conclusion
Prophylaxis administration with intravenous rHuEPO
three days before and at the time of anesthetic induc-
tion in patients undergoing cardiac surgery reduced
the incidence of clinically defined CSA-AKI, diminish
sensitive biomarker urine NGAL and improve the
clinical outcomes. A preconditioning regimen based
on high dose rHuEPO administration could be more
effective in preventing CSA-AKI. More studies are
needed to confirm the usefulness of this regimen and
larger studies are needed to assess the long term
outcomes.eline), 3 hr, 6 hr, 12 hr, 18 hr, and 24 hr after operation
injury
6 hr 12 hr 18 hr 24 hr
174 ± 134 164 ± 113 137 ± 95 122 ± 87
109 ± 64# 114 ± 67# 101 ± 62* 93 ± 56
296 ± 140 271 ± 81 207 ± 107 173 ± 105
167 ± 40# 164 ± 57# 128 ± 55* 101 ± 52*
106 ± 66 104 ± 79 98 ± 60 94 ± 61
100 ± 64 106 ± 66 97 ± 64 92 ± 58
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